Innate Immunity in Cardiovascular Diseases-Identification of Novel Molecular Players and Targets.

J Clin Med · 2023 · PMC9821340 · PMID 36615135

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Thus, pioneering clinical studies include RNAi drugs targeting liver synthesis of PCSK9, resulting in highly significant lowering of LDL cholesterol or targeting liver transthyretin (TTR) synthesis for treatment of cardiac TTR amyloidosis.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.